Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2023-06-07
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects and best dose of venetoclax when given
together with enzalutamide and to see how well they work in treating patients with castration
resistant prostate cancer that has spread to other places in the body. Androgens can cause
the growth of prostate cancer cells. Drugs, such as enzalutamide, may lessen the amount of
androgens made by the body. Venetoclax may target a special group of prostate cancer cells
that is known to lead to resistance to treatment. Giving enzalutamide and venetoclax may work
better in treating patients with castration resistant prostate cancer.